NASDAQ: NNOXNano X Imaging Ltd Stock
$1.32+0.02 (+1.54%)
Updated Jul 6, 2026
NNOX Price
$1.32
Fair Value Price
N/A
Market Cap
$91.87M
52 Week Low
$0.73
52 Week High
$5.69
P/E
-1.15x
P/B
0.73x
P/S
10.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.52M
Earnings
-$76.04M
Gross Margin
-84.9%
Operating Margin
-542.14%
Profit Margin
-523.8%
Debt to Equity
0.15
Operating Cash Flow
-$44M
Beta
1.84
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
NNOX Overview
Nano-X Imaging Ltd. specializes in developing a commercial-grade tomographic imaging device that incorporates an innovative digital X-ray source, which leverages a digital micro-electro-mechanical systems (MEMS) semiconductor cathode. Beyond its hardware focus, the company also delivers teleradiology services and creates artificial intelligence (AI) applications tailored for practical use in medical imaging. Its core offerings include the Nanox.ARC, a prototype medical imaging system that integrates its proprietary digital X-ray technology, and Nanox.CLOUD, a complementary cloud-based software platform envisioned to facilitate medical screening as a service. Nano-X also operates Nanox.MARKETPLACE, a platform designed to connect imaging facilities and customers with radiologists for efficient remote interpretation of medical scans. Additionally, the company provides AI-driven software solutions to a wide range of healthcare entities, including hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers. These solutions are designed to analyze data from existing computed tomography (CT) scans to identify or predict undiagnosed or underdiagnosed medical conditions, such as osteoporosis and cardiovascular disease. Nano-X further offers Teleradiology Services, delivering remote imaging interpretation to radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities, and multi-specialty physician groups. Founded in 2011, Nano-X Imaging Ltd. is headquartered in Neve Ilan, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NNOX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
NNOX
Ranked#77 of 94
Ranked#77 of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $11.78 | A | |
| $46.31 | A | |
| $31.87 | A |
Be the first to know about important NNOX news, forecast changes, insider trades & much more!
NNOX News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NNOX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NNOX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NNOX is good value based on its book value relative to its share price (0.73x), compared to the US Medical Devices industry average (3.11x)
P/B vs Industry Valuation
NNOX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NNOX due diligence checks available for Premium users.
Valuation
NNOX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.15x
Industry
20.88x
Market
6.94x
NNOX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.73x
Industry
3.11x
NNOX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NNOX's financial health
Profit margin
Revenue
$4.3M
Net Income
-$14.3M
Profit Margin
-330.9%
NNOX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NNOX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$145.8M
Liabilities
$19.5M
Debt to equity
0.15
NNOX's short-term assets ($51.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NNOX's short-term assets ($51.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NNOX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NNOX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.0M
Investing
$8.7M
Financing
$0.0
NNOX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NNOX vs Medical Device Stocks
Nano X Imaging Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.